• Nika Pharmaceuticals posted a net loss of USD 13,359 for the quarter ended March 31, 2026, widening from USD 12,945 a year earlier.
• Operating expenses rose to USD 13,359 from USD 12,945, with general and administrative costs increasing to USD 2,639 while professional fees edged down to USD 10,720.
• Cash ended the quarter at USD 1,530, down from USD 1,889 at Dec. 31, 2025, as net cash used in operating activities totaled USD 13,359.
• Related parties provided USD 13,000 in financing during the quarter, lifting amounts due to related parties to USD 331,624 from USD 318,624 at year-end.
• Business updates included issuance of 1,000,000 common shares under the Nika BioTechnology merger terms, plus a March 5, 2026 consultancy agreement with MD Global Partners to support capital raising and potential transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nika Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001826466-26-000039), on May 12, 2026, and is solely responsible for the information contained therein.